PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
62.73 USD
-0.03 (-0.05%)
62.73 USD
0 (0%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PBH gets an excellent profitability rating and is at the same time showing great financial health properties. PBH has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
PBH had a positive operating cash flow in the past year.
PBH had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
PBH has a Return On Assets of 5.83%. This is amongst the best in the industry. PBH outperforms 86.91% of its industry peers.
With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 85.86% of the companies in the same industry.
PBH has a better Return On Invested Capital (7.88%) than 85.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 18.09%, PBH belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
PBH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.00%, PBH belongs to the top of the industry, outperforming 94.24% of the companies in the same industry.
PBH's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 56.10%, PBH is doing good in the industry, outperforming 68.06% of the companies in the same industry.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.57 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.57. This is in the better half of the industry: PBH outperforms 62.83% of its industry peers.
PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.97, PBH belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.55, PBH is doing worse than 66.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.57 |
ROIC/WACC0.89
WACC8.89%
2.3 Liquidity
PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.70, PBH perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
PBH has a Quick Ratio of 2.51. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.51, PBH is in line with its industry, outperforming 51.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.15% over the past year.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
PBH shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.13% on average per year.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PBH is valuated correctly with a Price/Earnings ratio of 13.76.
87.43% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.92. PBH is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 12.81 indicates a correct valuation of PBH.
Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 84.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.57. PBH is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.76 | ||
| Fwd PE | 12.81 |
4.2 Price Multiples
PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 87.96% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 88.48% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.81 | ||
| EV/EBITDA | 10.47 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)8.38
PEG (5Y)1.55
EPS Next 2Y3.96%
EPS Next 3Y3.41%
5. Dividend
5.1 Amount
PBH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
62.73
-0.03 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners108.83%
Inst Owner Change0%
Ins Owners1.31%
Ins Owner Change0.82%
Market Cap3.02B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (26.02%)
Short Float %4.5%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)0%
PT rev (3m)-7.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.76 | ||
| Fwd PE | 12.81 | ||
| P/S | 2.72 | ||
| P/FCF | 11.81 | ||
| P/OCF | 11.45 | ||
| P/B | 1.65 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.47 |
EPS(TTM)4.56
EY7.27%
EPS(NY)4.9
Fwd EY7.8%
FCF(TTM)5.31
FCFY8.47%
OCF(TTM)5.48
OCFY8.73%
SpS23.1
BVpS37.96
TBVpS-20.68
PEG (NY)8.38
PEG (5Y)1.55
Graham Number62.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.57 |
F-Score7
WACC8.89%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y1.64%
EPS Next 2Y3.96%
EPS Next 3Y3.41%
EPS Next 5Y4.13%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.01%
Revenue Next 2Y0.22%
Revenue Next 3Y0.49%
Revenue Next 5Y1.15%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y3.05%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
What is the profitability of PBH stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.64% in the next year.